Positive Outlook for Rocket Pharmaceuticals Amidst Regulatory Progress and Financial Stability

Needham analyst Gil Blum has maintained their bullish stance on RCKT stock, giving a Buy rating today.

Gil Blum’s rating is based on several key factors that highlight Rocket Pharmaceuticals’ potential for growth. The company is making progress with its pivotal study on RP-A501 for Danon disease, with dosing still ongoing and an update expected in the first half of 2025. Additionally, Rocket is working towards resolving regulatory issues related to RP-L102 and aims to finalize its BLA submission within the year.
Financially, Rocket Pharmaceuticals is in a strong position, having ended the year with $372 million, which includes recent financing efforts. This financial stability is expected to support operations until the third quarter of 2026. Despite lowering the price target to $42 due to increased dilution and adjusted launch timelines, the overall outlook remains positive, justifying the Buy rating.